
Opinion|Videos|August 28, 2024
Impact of GnRH Agonists and Antagonists on Cardiovascular Outcomes in Prostate Cancer
Stephen Freedland, MD, discusses the role of GnRH agonists and antagonists on improving cardiovascular outcomes in patients with prostate cancer.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What insights do data show regarding GnRH agonists and GnRH antagonists and cardiovascular outcomes? If a patient has prior CVD, should they be treated with a GnRH antagonist?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
3
FDA approves first-line Zenflow system for the treatment of BPH
4
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
5





















